Editas Medicine Receives FDA Orphan Drug Designation For EDIT-301 For The Treatment Of Sickle Cell Disease

Editas Medicine, Inc. announced that the US FDA granted Orphan Drug Designation to EDIT-301, an investigational, gene-editing medicine, for the treatment of sickle cell disease.